Securing your building's safety with fastenings manufacturer SFS UK
Jul 26, 2023Turkish Space Agency President Serdar Hüseyin Yıldırım: "They Create Earthquakes Thanks to Weapons in Space" » Expat Guide Turkey
Jul 16, 2023Scott intros new Swing fly rods, built for those who do
Jul 20, 2023Earnings Flash (ATI) ATI Posts Q2 Revenue $1.05B, vs. Street Est of $1.07B
Jul 10, 2023Allegheny Technologies: Q2 Earnings Snapshot
Jul 12, 2023Bioretec to increase production capacity for bioresorbable implants
June 13, 2023 By Sean Whooley
Tampere, Finland-based Bioretec said its acquisition is optimized for the production of magnesium-based implants. This especially includes the first product from the RemeOs family, the RemeOs screw. Bioretec’s RemeOs screw received FDA approval in March.
According to the company, the screw is the first and only bioresorbable metal implant approved by the FDA. The product’s range and indication align with a clinical trial conducted in the ankle, Bioretec says. Its bioresorbable metals combine surgical techniques from traditional metal implants with the benefits of last-generation bioresorbable polymer implants. These make implant removal operations redundant, according to Bioretec.
Bioretec designed its products to enhance bone growth and accelerate fracture healing after orthopedic surgery. RemeOs implants are resorbed and replaced by bone. This eliminates the need for removal surgery while facilitating healing.
“The new CNC machining center will significantly increase our production capacity of RemeOs screws for the U.S. market. We estimate the commissioning of the machine to take place at the beginning of next year considering the current delivery time of 5-6 months. The addition of our own machining center for RemeOs™ products will also enhance the production of our Activa implants,” said Bioretec CEO Timo Lehtonen.
Filed Under: Business/Financial News, Implants, Metal-on-Metal, Orthopedics Tagged With: Bioretec